Abbott Laboratories vs. Dyne Therapeutics, Inc. Common Stock
Abbott Laboratories (ABT) comes out ahead, leading on 6 of 6 compared factors.
Size & Scale
| ABT | DYN | |
|---|---|---|
| Market Cap | $182.59 billion | $3.79 billion |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | $-519,406,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | DYN | |
|---|---|---|
| P/E Ratio | 34.15 | — |
| Price / Book | 3.53 | 5.40 |
| Price / Sales | 3.92 | — |
ABT leads on 1 of 1 valuation factors.
Profitability
| ABT | DYN | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | -73.97% |
ABT leads on 1 of 1 profitability factors.
Dividend
| ABT | DYN | |
|---|---|---|
| Dividend Yield | 2.39% | — |
| Payout Ratio | 81.55 | — |
ABT and DYN split the dividend factors evenly.
Risk & Sentiment
| ABT | DYN | |
|---|---|---|
| Short Interest | 0.57% | 11.72% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, DYN overview, DYN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.